Drug guidance
Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus
Condition
Endocrine and metabolic
31 August 2022
Published on 16 Oct 2017
Last Updated on 31 Aug 2022
Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus Guidance is outdated and has been withdrawn on 31 August 2022.
Insulin Glargine Biosimilar (Withdrawn 31 Aug 22) [PDF, 295 KB]